Christopher R. Ensor, PharmD, BCPS
Assistant Professor, Pharmacy and Therapeutics; Clinical Faculty, Thoracic Transplantation; Co-Director, Pharmacotherapy Scholars Program
PharmD, University of Rhode Island; Residencies, Virginia Commonwealth University/Medical College of Virginia Hospitals, Richmond, VA; Board Certified in Pharmacotherapy, Board of Pharmacy Specialties
Novel immunomodulatory strategies in thoracic transplantation
Chronic allograft dysfunction and humoral responses: Bronchiolitis obliterans syndrome remains the salient late morbidity and is responsible for the preponderance of late mortality after lung transplantation. Innate and adaptive immunoresponses are implicated in the development of BOS. Antibodies directed at the allograft, both of an anti HLA and directed at self-antigen nature, are responsible for significant increases in early BOS and death after lung transplantation. In collaboration with Drs. Zeevi, Lakkis, and McDyer, we study the impact of such mechanistic responses on the clinical allograft and identify targets and appraches to downregulate these pathways using novel immunotherapeutic and immunobiologic strategies.
Rejection characterization and immunosuppression monitoring: Characterization of rejection outcomes broadly and the associated assessment of various immunosuppressive strategies is challenging after lung transplantation. In collaboration with Dr. Venkataramanan, we study the impact of novel composite rejection and immunosuppression scores on the precise ability to quantitate differences in various standard and novel immunomodulatory strategies.